Knopp Biosciences to Present at Piper Jaffray 31st Annual Healthcare Conference

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York, NY on December 3-5.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Tuesday, November 12, 2019
Information
Tags: 
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Dexpramipexole, Thiazoles, Encephalopathy
Geotags: 
PENNSYLVANIA, NEW YORK, Europe, United States
⚠generated by AI ↴
Summary
Key Points: 
  • Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York, NY on December 3-5.
  • Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, December 3rd at 8:10 a.m. Eastern Time.
  • Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need.
  • In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopps preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy, non-opioid treatments for pain, and other CNS hyperexcitability disorders.


Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need, today announced that management will present at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York, NY on December 3-5.

Michael Bozik, M.D., President and CEO of Knopp Biosciences, is scheduled to present on Tuesday, December 3rd at 8:10 a.m. Eastern Time.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy, non-opioid treatments for pain, and other CNS hyperexcitability disorders. Please visit www.knoppbio.com.

Copyright: 
Copyright Business Wire 2019